Chimerix names new chief commercial officer
This article was originally published in Scrip
Chimerix, a biopharmaceutical company developing oral antivirals in areas of high unmet need, has appointed Linda M Richardson chief commercial officer. She will be responsible for establishing the company's commercial infrastructure and building its capabilities for the potential launch of lead compound brincidofovir. Prior to joining the Durham, North Carolina-based firm Ms Richardson was vice-president and head of the global lixisenatide franchise at Sanofi.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.